Kim Y - Search Results

1

Increased in vivo efficacy of lenalidomide and thalidomide by addition of ethacrynic acid.

Schmidt M, Kim Y, Gast SM, Endo T, Lu D, Carson D, Schmidt-Wolf IG. Schmidt M, et al. Among authors: kim y. In Vivo. 2011 May-Jun;25(3):325-33. In Vivo. 2011. PMID: 21576405

2

Prevention of lethal tumor growth and generation of long-lasting immunity in vivo using CD137L and interleukin-12 gene transfer.

Kim Y, Strehl JW, Gorschlüter M, Ziske C, Schmidt-Wolf IG. Kim Y, et al. In Vivo. 2008 May-Jun;22(3):337-43. In Vivo. 2008. PMID: 18610746 Free article.

3

CD40L-transfected myeloma cells transfer prolonged immunity in vivo.

Kim Y, Strehl JW, Sievers E, Gorschlüter M, Brossart P, Schmidt-Wolf IG. Kim Y, et al. In Vivo. 2010 Jan-Feb;24(1):45-8. In Vivo. 2010. PMID: 20133974

4

In vivo efficacy of griseofulvin against multiple myeloma.

Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D, Schmidt-Wolf IG. Kim Y, et al. Leuk Res. 2011 Aug;35(8):1070-3. doi: 10.1016/j.leukres.2010.10.008. Epub 2010 Nov 26. Leuk Res. 2011. PMID: 21112630

5

Increased in vivo efficacy of lenalidomide by addition of piroctone olamine.

Kim Y, Alpmann P, Blaum-Feder S, Krämer S, Endo T, Lu D, Carson D, Schmidt-Wolf IG. Kim Y, et al. In Vivo. 2011 Jan-Feb;25(1):99-103. In Vivo. 2011. PMID: 21282741

6

Targeting the Wnt/beta-catenin pathway with the antifungal agent ciclopirox olamine in a murine myeloma model.

Kim Y, Schmidt M, Endo T, Lu D, Carson D, Schmidt-Wolf IG. Kim Y, et al. In Vivo. 2011 Nov-Dec;25(6):887-93. In Vivo. 2011. PMID: 22021681

7

In vivo efficacy of the diuretic agent ethacrynic acid against multiple myeloma.

Kim Y, Gast SM, Endo T, Lu D, Carson D, Schmidt-Wolf IG. Kim Y, et al. Leuk Res. 2012 May;36(5):598-600. doi: 10.1016/j.leukres.2012.01.025. Epub 2012 Mar 2. Leuk Res. 2012. PMID: 22386728

8

Efficacy of a proapoptotic peptide towards cancer cells.

Jäkel CE, Meschenmoser K, Kim Y, Weiher H, Schmidt-Wolf IG. Jäkel CE, et al. Among authors: kim y. In Vivo. 2012 May-Jun;26(3):419-26. In Vivo. 2012. PMID: 22523294

9

Targeting cancer with a bi-functional peptide: in vitro and in vivo results.

Meschenmoser K, Kim Y, Franken S, Nowak M, Feldmann G, Bendas G, Wolfgarten M, Messmer D, Schmidt-Wolf IG. Meschenmoser K, et al. Among authors: kim y. In Vivo. 2013 Jul-Aug;27(4):431-42. In Vivo. 2013. PMID: 23812212

10

Targeting the Wnt/beta-catenin pathway in multiple myeloma.

Schmeel LC, Schmeel FC, Kim Y, Endo T, Lu D, Schmidt-Wolf IG. Schmeel LC, et al. Among authors: kim y. Anticancer Res. 2013 Nov;33(11):4719-26. Anticancer Res. 2013. PMID: 24222106

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

86,237 results

Search Page

Filters